poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $110

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDelveinsight

    Cancer Vaccines Clinical Trial Pipeline Boom as 200+ Companies are in the Race for Better Treatments | DelveInsight

    Over 200 companies are advancing cancer vaccine development with 200+ pipeline candidates in clinical trials. Recent positive Phase III results for intismeran autogene (mRNA-4157) in melanoma and encouraging data for TG4050 in head and neck cancer are driving momentum. However, challenges including clinical efficacy uncertainties, manufacturing complexity, high production costs, and patient selection barriers remain obstacles to broader commercialization.

  2. Globenewswire IncPrecedence Research

    Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

    The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

  3. The Motley FoolRj Fulton

    BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

    BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.